<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="outbreak caused by the Î²-coronavirus SARS-CoV originated in Guangdong in" exact="China" post="[21]. During the 2002â€&quot;2003 epidemic, approximately 8098 cases were"/>
 <result pre="causing a series of highly pathogenic respiratory tract infections in" exact="Saudi Arabia" post="and other Middle East countries [29]. Despite fears, the"/>
 <result pre="(SARS-CoV-2) was first detected in the city of Wuhan in" exact="China" post="in December 2019 [38,39]. It was thought to have"/>
 <result pre="of COVID-19 with intravenous administration of remdesivir took place in" exact="the US," post="leading to improvement in the patientâ€™s condition with a"/>
 <result pre="against several DNA and RNA viruses, has been approved in" exact="Russia" post="and China for prevention and treatment of influenza [100]."/>
 <result pre="DNA and RNA viruses, has been approved in Russia and" exact="China" post="for prevention and treatment of influenza [100]. Antiviral effect"/>
 <result pre="of disease in COVID-19 patients in the Hubei province in" exact="China" post="compared to other regions of the world [162]. Recently,"/>
 <result pre="use in 53 hospitalized COVID-19 patientsâ€&quot;of which, 22 were in" exact="the US," post="22 in Europe or Canada and 9 in Japan"/>
 <result pre="which, 22 were in the US, 22 in Europe or" exact="Canada" post="and 9 in Japan [169]. Thirty-six of the 53"/>
 <result pre="the US, 22 in Europe or Canada and 9 in" exact="Japan" post="[169]. Thirty-six of the 53 patients (68%) showed clinical"/>
 <result pre="patients were subjected to a clinical trial for remdesivir in" exact="China" post="[170]. Of the 237 patients enrolled in the study,"/>
 <result pre="and conducting trials at 180 sites in China, France, Germany," exact="Hong Kong," post="Italy, Japan, Korea, the Netherlands Singapore, Spain, Sweden, Switzerland,"/>
 <result pre="sites in China, France, Germany, Hong Kong, Italy, Japan, Korea," exact="the Netherlands" post="Singapore, Spain, Sweden, Switzerland, Taiwan, the United Kingdom and"/>
 <result pre="in China, France, Germany, Hong Kong, Italy, Japan, Korea, the" exact="Netherlands" post="Singapore, Spain, Sweden, Switzerland, Taiwan, the United Kingdom and"/>
 <result pre="Japan, Korea, the Netherlands Singapore, Spain, Sweden, Switzerland, Taiwan, the" exact="United Kingdom" post="and the United States. In the second SIMPLE trial,"/>
 <result pre="Netherlands Singapore, Spain, Sweden, Switzerland, Taiwan, the United Kingdom and" exact="the United States." post="In the second SIMPLE trial, the safety and efficacy"/>
 <result pre="Singapore, Spain, Sweden, Switzerland, Taiwan, the United Kingdom and the" exact="United States." post="In the second SIMPLE trial, the safety and efficacy"/>
 <result pre="Arbidol against Coronavirus Infection (ELACOI) single-blind randomized controlled trial in" exact="China" post="included 44 patients with mild or moderate clinical status"/>
 <result pre="strainsVirology2005337859210.1016/j.virol.2005.04.01015914223 33.MeyerB.MullerM.A.CormanV.M.ReuskenC.B.RitzD.GodekeG.J.LattweinE.KalliesS.SiemensA.van BeekJ.et al.Antibodies against MERS coronavirus in dromedary camels," exact="United Arab Emirates," post="2003 and 2013Emerg. Infect. Dis.20142055255910.3201/eid2004.13174624655412 34.EckerleI.CormanV.M.MullerM.A.LenkM.UlrichR.G.DrostenC.Replicative Capacity of MERS"/>
</results>
